Compare HRMY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | MIRM |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 3.4B |
| IPO Year | 2020 | 2019 |
| Metric | HRMY | MIRM |
|---|---|---|
| Price | $38.92 | $67.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $51.33 | ★ $87.55 |
| AVG Volume (30 Days) | ★ 789.9K | 560.0K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $825,944,000.00 | $471,794,000.00 |
| Revenue This Year | $23.11 | $53.78 |
| Revenue Next Year | $16.15 | $19.91 |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | 21.13 | ★ 53.66 |
| 52 Week Low | $25.52 | $36.88 |
| 52 Week High | $40.93 | $78.55 |
| Indicator | HRMY | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 45.04 |
| Support Level | $38.12 | $63.23 |
| Resistance Level | $40.87 | $66.77 |
| Average True Range (ATR) | 1.25 | 3.05 |
| MACD | 0.04 | -0.46 |
| Stochastic Oscillator | 71.48 | 32.98 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.